BiotechTube
BianoGMP

BianoGMP

Munich, Germany· Est.
bianoscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BianoGMP is a specialized oligonucleotide CDMO based in Gera, Germany, leveraging over 15 years of scientific expertise in RNAi and oligonucleotide chemistry. The company provides end-to-end services, including design, synthesis, a wide array of modifications, comprehensive analytics, and scalable manufacturing up to GMP-grade material for clinical trials. Its business model is service-based, catering to biotech and pharmaceutical clients advancing oligonucleotide-based therapeutics, diagnostics, and research tools. BianoGMP operates as a private company, supporting a broad range of oligonucleotide classes such as siRNAs, ASOs, and CpG oligos.

Genetics & Genomics

Technology Platform

Integrated oligonucleotide CDMO platform offering custom synthesis, a wide array of chemical modifications, scalable manufacturing (nmol to mmol), validated analytical services (HPLC, MS), and GMP production for clinical supplies.

Opportunities

The growing pipeline of oligonucleotide therapeutics and increased outsourcing by biotech firms creates strong demand for specialized CDMO services.
Its EU-based GMP manufacturing offers a strategic supply chain option for global clients seeking regulatory diversity and quality assurance associated with German engineering standards.

Risk Factors

Revenue is entirely dependent on a fluctuating client project portfolio, creating client concentration risk.
The company operates in a competitive CDMO landscape against larger, well-capitalized players and faces ongoing pressure to invest in keeping pace with rapid technological advancements in oligonucleotide chemistry and analytics.

Competitive Landscape

BianoGMP competes in the oligonucleotide CDMO space against large global players like Eurofins Genomics, LGC Biosearch Technologies, and Danaher (IDT), as well as other specialized European CDMOs. Its differentiation is based on deep RNAi expertise, a focus on complex modifications, GMP capability from a German base, and a positioning as a flexible, scientific partner rather than a high-volume commodity supplier.

More companies in RNA Therapeutics (non-mRNA) →More companies in Germany →